Who owns your GP clinic? Why insurer-backed care is raising questions about access and choice

A quiet shift in primary care ownership

Most people book a GP appointment assuming the clinic is simply a medical practice: doctors, nurses, reception staff, a waiting room, and the familiar rhythms of everyday healthcare. But in Australia, the ownership and funding landscape around general practice is changing. Major private health insurers, including Medibank Private and Bupa, have been open about buying, opening, and partnering with GP clinics and related services. At the same time, all four major insurers are offering free or heavily discounted telehealth-style GP consultations to their members.

This expansion is not just about branding or convenience. It has sparked a deeper debate about what happens when the organisations that pay for healthcare also begin to provide it. Doctors and professional bodies are warning about the potential for conflicts of interest, reduced patient choice, and the emergence of a two-tier system—where privately insured patients can access care more easily or more cheaply than those relying solely on Medicare.

Why the comparison to the United States keeps coming up

The debate is often framed by reference to the United States, where the healthcare system is widely seen as fragmented and unequal. In the US, it is not uncommon to see clinics effectively limiting access through signs such as “No Medicaid patients” or “Insured patients only”. Those signs reflect a system where uninsured people can face worse health outcomes, and where even insured patients can be denied legitimate care.

Medicaid in the US is a government-subsidised healthcare program for low-income earners. It is not the same as Australia’s Medicare. In the US, doctors can opt out of Medicaid, and sometimes do, because reimbursement rates are low. The result is that access can depend on the type of coverage a patient has, and on whether a clinic chooses to accept it.

Australia’s system is different in important ways, and insurers emphasise that point. But doctors are increasingly concerned that certain incentives—particularly when insurers own or heavily influence service delivery—could push Australia toward some features of an insurer-directed model of care often referred to as “managed care”.

Medicare pressure and the risk of “No Medicare” telehealth

Australian GPs have long argued that Medicare rebates do not keep pace with the costs of running a practice. Against that backdrop, the idea of “No Medicare” doctors has moved from being unthinkable to becoming a real concern—especially in online and telehealth settings.

The growth of insurer-funded telehealth is central to this concern. Insurers are offering some consultations free or at heavily discounted prices for their members. The key detail is that these telehealth consultations are not covered by Medicare. Instead, insurers are paying the full cost themselves. This arrangement is legal due to the confluence of two laws that together make it possible.

On its face, cheaper telehealth might look like a straightforward win for patients. Insurers also say anyone can access these telehealth services, which is true. But the price point matters. If members can access the same service more cheaply than non-members, it can create a second tier of access: those with private insurance may find it easier to get care because it is more affordable to them.

A two-tier system: the access problem in a GP shortage

Concerns about a two-tier system are sharpened by another reality: Australia has a shortage of GPs. Australian Medical Association vice president Julian Rait has pointed to the potential for insurer-led GP services to attract doctors to their organisations, particularly if they can offer better pay or different working conditions.

In a tight workforce market, any model that draws clinicians into one network can have ripple effects across the broader system. If more doctors choose insurer-backed clinics or telehealth platforms, other practices—especially those relying heavily on Medicare rebates—may find it harder to recruit and retain staff. That could further affect appointment availability for patients who are not privately insured.

This is the context in which the phrase “No Medicare” becomes more than a rhetorical warning. The fear is not necessarily a sign on a clinic door, but a gradual shift in where clinicians choose to work and where patients can most easily access timely care.

Insurers expanding beyond GP care

The insurer push is not limited to GP clinics and telehealth. Medibank, for example, is buying up private hospitals and offering “hospital in the home” care services through its subsidiary Amplar Health. This broader expansion has intensified concern among some doctors that Australia may be moving, step by step, toward an insurer-directed system.

In such a system, insurers are not only paying claims but also shaping pathways: where patients go, what services they receive, and how care is coordinated. Supporters may argue that this can reduce duplication and improve efficiency. Critics worry it can prioritise cost control over clinical independence and patient choice.

The conflict-of-interest question: referrals and networks

The Australian Medical Association has raised a specific concern: if a health insurer owns a GP clinic, it may create incentives for doctors to refer patients to the insurer’s own hospitals or a preferred network of specialists. There are rules intended to prevent improper steering. Even so, the AMA argument is that the conflict of interest can be too great, and the potential for perverse incentives too high.

Referrals are a practical example of how influence can operate even without explicit direction. Patients can take a named referral to any provider. But in reality, many patients rely on their doctor’s guidance on which specialist to see or which hospital suits their condition. If the clinic is owned by an insurer, critics argue that subtle pressures—whether financial, administrative, or cultural—could shape those recommendations.

From the patient perspective, the risk is that cost-saving measures could translate into fewer options. Insurers may be trying to save patients money, but the trade-off can be less choice. And as critics point out, when there is less choice, one thing can happen: prices go up.

Government position and the debate about what is already emerging

Health Minister Mark Butler has said the government does not support a two-tier system. Yet doctors and other observers argue that elements of a two-tier system are already beginning to emerge, driven by differential pricing and access in insurer-backed services.

This tension—between stated policy goals and market developments—sits at the centre of the debate. If private insurers are increasingly able to offer cheaper access to certain services for members, and if those services attract clinicians away from Medicare-dependent practice models, inequities could deepen even without any formal change to Medicare itself.

How Australia differs from the US—and why concerns remain

Insurers argue loudly that Australia is not the United States. There are real structural differences. In Australia, anyone can buy private health insurance under a community rating system, and cover is not offered through employers in the same way it often is in the US. Insurers are also tightly regulated in what they can and cannot cover through the Basic-to-Gold policy system. They must also mostly mirror the Medicare committees that decide what is and is not covered.

These protections matter. They reduce the risk of some of the most extreme outcomes seen in other systems. But critics say regulation does not eliminate the incentive for insurers to expand into new health spaces and push the boundaries of influence whenever laws allow.

Signs of insurer encroachment in private hospital care

Some specialists say they are already seeing more insurer involvement in clinical and hospital-related decisions. Orthopaedic surgeons, who do a large share of private hospital work, report concerns including policies not covering certain prostheses they would like to use. There are also claims about rehabilitation limits in insurer contracts with hospitals, although the industry disputes those claims.

Another example raised in the debate comes from an ombudsman’s review of type C certificates. These certificates can allow a procedure that is normally done in a specialist’s rooms to be done in a hospital and claimed on private health insurance. One scenario described is a Parkinson’s patient who might need sedation to allow an eye injection. The ombudsman found some health insurers were questioning these certificates and leaving them in limbo—effectively rejecting claims through inertia.

For clinicians, these experiences feed the broader fear that insurers may increasingly shape what care is delivered, where it is delivered, and how quickly claims are processed—factors that can influence clinical decisions and patient outcomes even when the intent is cost control or administrative scrutiny.

Preventive care pilots: promise, but also incentives

Not every insurer initiative is framed as restrictive. Some are presented as preventive and patient-focused. A pilot project in preventive health was launched in 2024 at three Myhealth medical centres. A preventive care pilot run by Medibank Private in western Sydney is described as accessible to anyone.

Preventive care is widely seen as valuable, and many Australians may welcome a stronger focus on prevention and telehealth. But the ownership and incentive structure remains part of the debate. Even if a program is open to all, the insurer still stands to benefit if it reduces hospitalisations—and therefore reduces insurance claims—for its members.

There is no suggestion that there is anything wrong with the pilot itself. The concern is theoretical but important: what happens if insured patients receive preferential treatment, or if patients are directed toward particular health interventions, providers, or timelines in ways that align more closely with insurer incentives than with patient preference?

What patients should watch for in an evolving market

For patients, the most immediate experience of these changes may be subtle: a discounted telehealth appointment here, a new clinic brand there, or a recommendation that seems to fit neatly within one network. The bigger picture is about how access, affordability, and choice are shaped over time when insurers become both funders and providers.

Key issues raised by doctors and critics can be summarised as follows:

• Access and affordability: discounted or free consultations for members can make care easier to obtain for the privately insured, particularly when Medicare-backed options are under strain.
• Workforce distribution: in a GP shortage, insurer-backed services may attract clinicians away from practices that rely on Medicare rebates.
• Choice and independence: insurer ownership of clinics can raise concerns about referrals, preferred networks, and the subtle steering of patients.
• Claims and coverage influence: disputes over prostheses, rehabilitation limits, and the handling of claims processes can affect how care is delivered in private settings.

A system at a crossroads

Australia’s healthcare system still rests on Medicare as its foundation, and insurers remain subject to significant regulation. Yet the expansion of insurers into GP clinics, telehealth services, private hospitals, and home-based hospital care is changing the shape of the market.

The central question is not whether telehealth or preventive care is good—many would argue both are essential. The question is how these services are structured, who controls them, and whether their growth entrenches different levels of access depending on insurance status.

Doctors warning about “managed care” are not necessarily predicting an overnight transformation. The concern is incremental: partnerships here, acquisitions there, and new pricing models that gradually shift the balance of power in healthcare decision-making. As these models expand, the challenge for policymakers, regulators, clinicians, and patients will be to preserve equitable access and genuine choice—while still encouraging innovation that improves care.